• +1-646-491-9876
    • +91-20-67278686

    Search

    Cervical Intraepithelial Neoplasia Pipeline Review H1 2017

    Cervical Intraepithelial Neoplasia Pipeline Review H1 2017

    • Report Code ID: RW0001866813
    • Category Pharmaceuticals
    • No. of Pages 67
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

    Cervical intraepithelial neoplasia (CIN) , also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV) . Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 3 and 1 molecules, respectively.

    Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Cervical Intraepithelial Neoplasia (CIN) - Overview
    Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development
    CEL-SCI Corp
    CritiTech Inc
    Genexine Inc
    PDS Biotechnology Corp
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    THEVAX Genetics Vaccine USA Inc
    Transgene SA
    Vaccibody AS
    Cervical Intraepithelial Neoplasia (CIN) - Drug Profiles
    ABI-1968 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aminolevulinic acid hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Human Papilloma Virus Associated Cervical Intraepithelial Neoplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GLBL-101c - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GX-188E - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Multikine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDS-0101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-4001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TVGV-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target HPV E6 for Cervical Intraepithelial Neoplasia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VB-1016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vvax-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects
    Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products
    Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones
    Featured News & Press Releases
    Mar 23, 2017: Vaccibody Announces Vaccination Of First Patient In Its Phase IIA Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
    Mar 02, 2017: Vaccibody Announces Approval Of Amendment Of IMPD Allowing To Start Of Expansion Phase In Its Phase I/IIa Study With VB10.16 Immunotherapy For Patients With HPV16 Induced High Grade Lesions Of The Cervix
    Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016
    Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe
    Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe
    Jan 26, 2015: TheVax Genetics Vaccine Announces TVGV-1 Update
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CritiTech Inc, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by THEVAX Genetics Vaccine USA Inc, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H1 2017
    Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    CEL-SCI Corp
    CritiTech Inc
    Genexine Inc
    PDS Biotechnology Corp
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    THEVAX Genetics Vaccine USA Inc
    Transgene SA
    Vaccibody AS

    Request for Sample

    Report Url https://www.reportsweb.com//cervical-intraepithelial-neoplasia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//cervical-intraepithelial-neoplasia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//cervical-intraepithelial-neoplasia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments